KR102186872B1 - Skin whitening composition comprising milk exosomes - Google Patents
Skin whitening composition comprising milk exosomes Download PDFInfo
- Publication number
- KR102186872B1 KR102186872B1 KR1020190048320A KR20190048320A KR102186872B1 KR 102186872 B1 KR102186872 B1 KR 102186872B1 KR 1020190048320 A KR1020190048320 A KR 1020190048320A KR 20190048320 A KR20190048320 A KR 20190048320A KR 102186872 B1 KR102186872 B1 KR 102186872B1
- Authority
- KR
- South Korea
- Prior art keywords
- exosomes
- milk
- milk exosomes
- present
- skin
- Prior art date
Links
- 210000001808 exosome Anatomy 0.000 title claims abstract description 115
- 235000013336 milk Nutrition 0.000 title claims abstract description 96
- 239000008267 milk Substances 0.000 title claims abstract description 96
- 210000004080 milk Anatomy 0.000 title claims abstract description 96
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 230000002087 whitening effect Effects 0.000 title claims abstract description 25
- 108091032966 miR-2478 stem-loop Proteins 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 235000013305 food Nutrition 0.000 claims description 11
- 208000031019 skin pigmentation disease Diseases 0.000 claims description 10
- 239000002537 cosmetic Substances 0.000 claims description 8
- 241000283690 Bos taurus Species 0.000 claims description 5
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 3
- 102000003425 Tyrosinase Human genes 0.000 description 38
- 108060008724 Tyrosinase Proteins 0.000 description 38
- 230000014509 gene expression Effects 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 30
- 230000000694 effects Effects 0.000 description 28
- 102000013760 Microphthalmia-Associated Transcription Factor Human genes 0.000 description 25
- 108010050345 Microphthalmia-Associated Transcription Factor Proteins 0.000 description 25
- 210000003491 skin Anatomy 0.000 description 23
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 18
- 230000008099 melanin synthesis Effects 0.000 description 18
- 230000002401 inhibitory effect Effects 0.000 description 17
- 108020004999 messenger RNA Proteins 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 238000009472 formulation Methods 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 11
- 230000036541 health Effects 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- -1 for example Substances 0.000 description 9
- 239000002679 microRNA Substances 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 108700011259 MicroRNAs Proteins 0.000 description 7
- 238000012790 confirmation Methods 0.000 description 7
- 235000013376 functional food Nutrition 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 208000012641 Pigmentation disease Diseases 0.000 description 5
- 102000040945 Transcription factor Human genes 0.000 description 5
- 108091023040 Transcription factor Proteins 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 210000002510 keratinocyte Anatomy 0.000 description 5
- 210000002752 melanocyte Anatomy 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000019612 pigmentation Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 238000002296 dynamic light scattering Methods 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 108091070501 miRNA Proteins 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 208000035859 Drug effect increased Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000004321 EU approved sweetener Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000010818 SYBR green PCR Master Mix Methods 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 206010070835 Skin sensitisation Diseases 0.000 description 1
- 239000012163 TRI reagent Substances 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000001058 brown pigment Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000012200 cell viability kit Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000005016 dendritic process Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 229960004337 hydroquinone Drugs 0.000 description 1
- 208000000069 hyperpigmentation Diseases 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000036564 melanin content Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 231100000370 skin sensitisation Toxicity 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/986—Milk; Derivatives thereof, e.g. butter
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/606—Nucleosides; Nucleotides; Nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Abstract
본 발명은 우유 엑소좀을 포함하는 피부 미백용 조성물에 관한 것이다.The present invention relates to a composition for skin whitening comprising milk exosomes.
Description
본 발명은 우유 엑소좀을 포함하는 피부 미백용 조성물에 관한 것이다.The present invention relates to a composition for skin whitening comprising milk exosomes.
사람의 피부색을 결정하는 멜라닌(melanin)은 멜라노사이트(melanocyte)에서 생성된다. 구체적으로 멜라닌은 생체 내 존재하는 아미노산인 티로신(tyrosine)을 기질로 하여, 멜라노사이트에 존재하는 티로시나제(tyrosinase) 등의 효소에 의한 중합화 산화 반응으로 형성되는 흑갈색의 색소이다. 이렇게 형성된 멜라닌은 멜라노사이트의 수지상 돌기를 통하여 케라티노사이트(keratinocyte)라는 표피세포로 이동하게 된다. 케라티노사이트로 이동한 멜라닌은 케라티노사이트가 표피에서 떨어져 나갈 때에 피부에서 함께 떨어져 나감으로써 제거될 수 있다. 그러나, 생체 내에 멜라닌을 분해하는 효소가 없기 때문에 한번 형성된 멜라닌은 생체 내에서는 분해되지 않는다. 따라서, 피부를 밝게 하기 위하여는 멜라닌의 생성을 억제하는 것이 관건이라 할 수 있다. Melanin, which determines the color of human skin, is produced in melanocytes. Specifically, melanin is a dark brown pigment formed by polymerization and oxidation reactions by enzymes such as tyrosinase present in melanocytes using tyrosine, an amino acid present in vivo, as a substrate. The melanin formed in this way moves to epidermal cells called keratinocytes through dendritic processes of melanocytes. Melanin that has migrated to keratinocytes can be removed by releasing them together from the skin as the keratinocytes break away from the epidermis. However, since there is no enzyme that degrades melanin in the living body, melanin once formed is not degraded in vivo. Therefore, in order to brighten the skin, it can be said that suppressing the production of melanin is the key.
최근 정서적으로 흰 피부를 선호하는 동양권의 생활 수준 향상과 더불어 피부 흑화가 자외선에 의한 피부 노화로 인식되면서 미백 및 색소 침착 억제에 관한 연구의 필요성이 점차 증대되고 있다. 그에 따라 아스코르빈산(ascorbic acid), 하이드로퀴논(hydroquinone), 글루타치온(glutathione), 알부틴(arbutin) 등의 티로시나아제 저해 활성을 나타내는 물질들이 화장료나 의약품에 배합되어 사용되어 왔으나, 이들 중 대부분의 것은 효과가 불충분하거나 제형상 불안정한 면이 있어 활용도가 떨어진다. 특히 하이드로퀴논과 같은 화합물은 강한 탈색 작용을 나타내며 그 자체가 피부 감작성을 가지고 있어 피부 알레르기 등을 유발할 수 있고, 정상적인 피부의 기능을 변화시켜 백반증을 유발하는 등의 부작용을 나타내어 피부에 대한 안전성 측면에서 그 사용이 제한되고 있다. Recently, the need for research on whitening and pigmentation suppression is gradually increasing as skin blackening is recognized as skin aging due to ultraviolet rays along with the improvement of living standards in the Eastern world, which emotionally prefers white skin. Accordingly, substances exhibiting tyrosinase inhibitory activity such as ascorbic acid, hydroquinone, glutathione, and arbutin have been formulated and used in cosmetics and pharmaceuticals, but most of these It is less effective because it has insufficient effect or is unstable in its formulation. In particular, compounds such as hydroquinone exhibit a strong bleaching action and have skin sensitization by themselves, which can cause skin allergies and other side effects, such as causing vitiligo by changing the normal skin function. Its use is limited in.
또한, 상기와 같이 티로시나아제의 활성을 저해하는 물질이라 하더라도 이러한 물질이 각질 형성 세포인 케라티노사이트에 작용하여 멜라닌의 생합성을 촉진시키는 인자의 생성을 증가시킨다면, 결과적으로 미백 작용은 약화되거나 오히려 악효과를 거둘 수 있기 때문에 단순히 티로시나아제의 활성 저해제가 좋은 미백제라고 볼 수 없으며, 이에 많은 티로시나아제 저해제가 개발되고 있으나 거의 대부분이 우수한 미백 효과를 나타내지 않는 것으로 알려져 있다.In addition, even if it is a substance that inhibits the activity of tyrosinase as described above, if these substances act on keratinocytes, which are keratinocytes, to increase the production of factors that promote the biosynthesis of melanin, as a result, the whitening effect is weakened or rather Since it can have an adverse effect, simply an inhibitor of tyrosinase activity cannot be considered as a good whitening agent. Accordingly, many tyrosinase inhibitors have been developed, but most of them are known to exhibit no excellent whitening effect.
이에 따라, 미백 또는 색소 침착 억제 효과가 우수한 물질에 대한 연구 및 개발이 요구되고 있다.Accordingly, there is a need for research and development on materials having excellent whitening or pigmentation inhibitory effects.
본 발명의 목적은 우유 엑소좀을 포함하는, 피부 미백용 조성물을 제공하는 것이다. It is an object of the present invention to provide a composition for skin whitening, including milk exosomes.
본 발명의 다른 목적은 우유 엑소좀을 포함하는, 피부 색소 침착 질환의 예방 또는 치료용 약학적 조성물 제공하는 것이다.Another object of the present invention is to provide a pharmaceutical composition for preventing or treating skin pigmentation diseases, including milk exosomes.
상기와 같은 목적을 달성하기 위한 본 발명의 일 측면은 우유 엑소좀을 포함하는, 피부 미백용 조성물에 관한 것이다.One aspect of the present invention for achieving the above object relates to a composition for skin whitening, including milk exosomes.
본 발명에서, “우유 엑소좀”은 우유 유래의 지질 이중충의 소낭을 말한다. 상기 엑소좀은 우유 유래의 고유의 단백질 및 핵산 등을 포함하고 있으며 30~200 nm 크기의 생체 나노입자로, 내부에 DNA, RNA, 펩타이드 등으로 이루어진 정보가 담겨있다. 엑소좀은 내부의 물질을 체액 내 분해 효소 등으로부터 안전하게 운반하여 인접 세포 또는 원거리 세포에 정보 전달을 하여 세포 주변의 미세 환경에 영향을 미친다. 특히, 우유 유래의 우유 엑소좀은 식품으로도 접할 수 있을 뿐만 아니라 많은 양의 엑소좀이 추출되며, 긴 시간 동안 안정한 상태로 보관할 수 있다는 장점이 있다.In the present invention, the "milk exosome" refers to a vesicle of a lipid biworm derived from milk. The exosomes contain milk-derived proteins and nucleic acids, and are biological nanoparticles having a size of 30 to 200 nm, and contain information including DNA, RNA, and peptides. Exosomes safely transport internal substances from degrading enzymes in body fluids and transmit information to adjacent cells or distant cells, affecting the microenvironment around cells. In particular, milk-derived milk exosomes have the advantage of not only being able to come into contact with food, but also extracting a large amount of exosomes and storing them in a stable state for a long time.
본 발명에서, “미백”은 피부를 하얗게 하는 것을 의미하며 멜라닌의 과도한 합성이나, 티로시나아제 효소의 활성, L-DOPA의 과도한 산화 등으로 인한 기미, 주근깨 등의 다양한 색소 침착을 완화 또는 개선하는 것을 말한다.In the present invention, "whitening" means to whiten the skin, and to relieve or improve various pigmentation such as spots and freckles caused by excessive synthesis of melanin, activity of tyrosinase enzyme, excessive oxidation of L-DOPA, etc. Say that.
구체적으로, 본 발명의 상기 우유 엑소좀은 서열번호 5의 염기서열로 이루어진 miR-2478을 포함하는 것일 수 있다. Specifically, the milk exosome of the present invention may include miR-2478 consisting of the nucleotide sequence of SEQ ID NO: 5.
본 발명 일 실시예에서는 본 발명의 우유 엑소좀이 세포 독성이 없음을 확인하였으며(도 4), 우유 엑소좀을 처리한 경우 티로시나아제의 활성 및 발현이 억제되고, 멜라닌 생합성을 촉진하는 전사인자인 MITF(microphthalmia-associated transcription factor) 의 발현 역시 억제됨을 확인하였다(도 5 내지 도 7). 특히, 피부에 색소를 침착시켜 피부를 어둡게 하는 멜라닌의 합성이 감소하는 것을 직접적으로 확인하였다(도 8). 또한, 본 발명의 우유 엑소좀 내에 마이크로 RNA인 miR-2478이 포함되어 있음을 확인하였다(도 9). In one embodiment of the present invention, it was confirmed that the milk exosomes of the present invention were not cytotoxic (FIG. 4), and when the milk exosomes were treated, the activity and expression of tyrosinase was inhibited, and a transcription factor that promotes melanin biosynthesis It was confirmed that the expression of phosphorus MITF (microphthalmia-associated transcription factor) was also suppressed (FIGS. 5 to 7 ). In particular, it was directly confirmed that the synthesis of melanin, which darkens the skin by depositing a pigment on the skin, decreases (FIG. 8). In addition, it was confirmed that miR-2478, a micro RNA, was contained in the milk exosomes of the present invention (FIG. 9).
구체적으로, 상기 피부 미백용 조성물은 화장료 조성물인 것일 수 있다.Specifically, the skin whitening composition may be a cosmetic composition.
본 발명의 화장료 조성물은 용액, 외용 연고, 크림, 폼, 영양 화장수, 유연 화장수, 팩, 유연수, 유액, 메이크업 베이스, 에센스, 비누, 액체 세정료, 입욕제, 선 스크린 크림, 선 오일, 현탁액, 유탁액, 페이스트, 겔, 로션, 파우더, 비누, 계면 활성제-함유 클렌징, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션, 패취 및 스프레이로 구성된 군으로부터 선택되는 제형으로 제조할 수 있으나, 이에 제한되는 것은 아니다.The cosmetic composition of the present invention is a solution, external ointment, cream, foam, nutrient lotion, flexible lotion, pack, softening water, emulsion, makeup base, essence, soap, liquid detergent, bathing agent, sunscreen cream, sun oil, suspension, emulsion It can be prepared in a formulation selected from the group consisting of liquid, paste, gel, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation, patch, and spray, but is limited thereto. no.
본 발명의 상기 화장료 조성물은 일반 피부 화장료에 배합되는 화장품학적으로 허용 가능한 담체를 1 종 이상 추가로 포함할 수 있으며, 통상의 성분으로 예를 들면 유분, 물, 계면 활성제, 보습제, 저급 알코올, 증점제, 킬레이트제, 색소, 방부제, 향료 등을 적절히 배합할 수 있으나, 이에 제한되는 것은 아니다.The cosmetic composition of the present invention may additionally include one or more cosmetically acceptable carriers blended in general skin cosmetics, and as common ingredients, for example, oil, water, surfactants, moisturizers, lower alcohols, thickeners , A chelating agent, a colorant, a preservative, a fragrance, and the like may be appropriately blended, but are not limited thereto.
본 발명의 화장료 조성물에 포함되는 화장품학적으로 허용 가능한 담체는 화장료 조성물의 제형에 따라 다양하다.The cosmetically acceptable carrier included in the cosmetic composition of the present invention varies depending on the formulation of the cosmetic composition.
본 발명의 제형이 연고, 페이스트, 크림 또는 젤인 경우에는, 담체 성분으로서 동물성 유, 식물성 유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크, 산화 아연 등이 이용될 수 있으나, 이에 제한되는 것은 아니다. 이들은 단독으로 사용되거나 2 종 이상 혼합되어 사용될 수 있다.When the formulation of the present invention is an ointment, paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide, etc. May be used, but is not limited thereto. These may be used alone or in combination of two or more.
본 발명의 제형이 파우더 또는 스프레이인 경우에는, 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록사이드, 칼슘 실케이트, 폴리아미드 파우더 등이 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로하드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진제를 포함할 수 있으나, 이에 제한되는 것은 아니다. 이들은 단독으로 사용되거나 2 종 이상 혼합되어 사용될 수 있다.When the formulation of the present invention is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder, etc. may be used as a carrier component. In particular, in the case of a spray, additional chlorofluorohard It may include a propellant such as locarbon, propane/butane or dimethyl ether, but is not limited thereto. These may be used alone or in combination of two or more.
본 발명의 제형이 용액 또는 유탁액인 경우에는, 담체 성분으로서 용매, 용해화제 또는 유탁화제 등이 이용될 수 있으며, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌 글리콜, 1,3-부틸글리콜 오일 등이 이용될 수 있고, 특히, 목화씨 오일, 땅콩 오일, 옥수수 배종 오일, 올리브 오일, 피마자 오일 및 참깨 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 이용될 수 있으나, 이에 제한되는 것은 아니다. 이들은 단독으로 사용되거나 2 종 이상 혼합되어 사용될 수 있다.When the formulation of the present invention is a solution or emulsion, a solvent, a solubilizing agent or an emulsifying agent may be used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, Propylene glycol, 1,3-butyl glycol oil, and the like may be used, and in particular, cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil, glycerol aliphatic ester, polyethylene glycol or fatty acid ester of sorbitan May be used, but is not limited thereto. These may be used alone or in combination of two or more.
본 발명의 제형이 현탁액인 경우에는, 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타하이드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있으나, 이에 제한되는 것은 아니다. 이들은 단독으로 사용되거나 2 종 이상 혼합되어 사용될 수 있다.When the formulation of the present invention is a suspension, as a carrier component, a liquid diluent such as water, ethanol or propylene glycol, an ethoxylated isostearyl alcohol, a suspending agent such as polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, micro Crystalline cellulose, aluminum metahydroxide, bentonite, agar, or tracant may be used, but are not limited thereto. These may be used alone or in combination of two or more.
또한, 본 발명의 조성물은 피부에 직접 도포하거나 살포하는 등의 경피 투여 방법으로 사용될 수 있으며, 본 발명 조성물의 투여 경로는 목적조직에 도달할 수 있는 한 어떠한 일반적인 경로를 통하여 투여될 수 있다. In addition, the composition of the present invention may be used as a transdermal administration method such as direct application or spraying on the skin, and the administration route of the composition of the present invention may be administered through any general route as long as it can reach the target tissue.
본 발명의 조성물의 사용량은 연령, 병변의 정도 등의 개인 차이나 제형에 따라 적절하게 조절될 수 있으며, 1일 1회 내지 수회 적?韜?을 피부에 도포하여 1 주일 내지 수개월 사용될 수 있다. The amount of use of the composition of the present invention may be appropriately adjusted according to individual differences or formulations such as age and degree of lesions, and may be used from one week to several months by applying one or several times a day to the skin.
또한 구체적으로, 상기 피부 미백용 조성물은 식품 조성물인 것일 수 있다. In addition, specifically, the skin whitening composition may be a food composition.
상기 식품의 종류에는 특별한 제한은 없다. 본 발명의 우유 엑소좀을 첨가할 수 있는 식품은 소세지, 육류, 빵, 초콜릿류, 스넥류, 캔디류, 과자류, 라면, 피자, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알코올 음료 및 비타민 복합제 등이 있다. 음료수로 제형화할 경우에 본 발명의 우유 엑소좀 외에 첨가되는 액체 성분으로는 이에 한정되지는 않으나, 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물은 모노사카라이드(예, 포도당, 과당 등), 디사카라이드(예, 말토오스, 수크로오스 등) 및 폴리사카라이드(예, 덱스트린, 시클로덱스트린 등과 같은 통상적인 당), 및 자일리톨, 소르비톨, 에리스리톨 등의 당 알코올일 수 있다.There is no particular limitation on the type of food. Foods to which the milk exosomes of the present invention can be added include sausage, meat, bread, chocolate, snacks, candy, confectionery, ramen, pizza, other noodles, gum, dairy products including ice cream, various soups, beverages, tea , Drinks, alcoholic beverages and vitamin complexes. In the case of formulation as a beverage, the liquid component added in addition to the milk exosomes of the present invention is not limited thereto, but may contain various flavoring agents or natural carbohydrates as an additional component, such as a conventional beverage. The natural carbohydrates described above are monosaccharides (e.g., glucose, fructose, etc.), disaccharides (e.g., maltose, sucrose, etc.) and polysaccharides (e.g., common sugars such as dextrin, cyclodextrin, etc.), and xylitol, sorbitol. And sugar alcohols such as erythritol.
상기 식품의 종류는 구체적으로 건강기능식품일 수 있다. 상기 건강기능 식품은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 증진제 (치즈, 초콜릿 등), 펙트산 및 그의 염, 유기산, 보호성 콜로이드 점증제, pH 조절제, 안정화제, 보존제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 또한, 본 발명의 건강기능 식품은 과일 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 단독으로 또는 조합으로 사용될 수 있으며, 이러한 첨가제의 비율은 조성물 전체 중량당 0.001 내지 50 중량부의 범위에서 선택되는 것이 일반적이다.The type of food may specifically be a health functional food. The health functional foods include various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavors and natural flavoring agents, coloring agents and enhancers (cheese, chocolate, etc.), pectic acid and its salts, organic acids, protective colloidal growth It may contain an agent, a pH adjuster, a stabilizer, a preservative, glycerin, alcohol, a carbonation agent used in carbonated beverages, and the like. In addition, the health functional food of the present invention may contain pulp for the manufacture of fruit and vegetable beverages. These components may be used alone or in combination, and the proportion of these additives is generally selected from 0.001 to 50 parts by weight per total weight of the composition.
상기 건강기능식품은 식품의 생체 조절 기능을 강조한 식품으로 물리적, 생화학적, 생물공학적인 방법을 이용하여 특정 목적에 작용 및 발현하도록 부가가치를 부여한 식품이다. 이러한 건강기능 식품의 성분은 생체 방어와 신체 리듬의 조절, 질환의 방지 및 회복에 관계하는 신체 조절 기능을 생체에 대하여 충분히 발휘하도록 설계하여 가공하게 되며, 식품으로 허용 가능한 식품 보조 첨가제, 감미료 또는 기능성 원료를 함유할 수 있다. The health functional food is a food that emphasizes the biological regulation function of food, and is a food that has added value to act and express it for a specific purpose by using physical, biochemical, and bioengineering methods. Ingredients of these health functional foods are designed and processed to fully exert the body's control functions related to body defense, regulation of body rhythm, prevention and recovery of diseases to the living body, and food additives, sweeteners, or functional foods acceptable as foods. It may contain raw materials.
본 발명의 우유 엑소좀을 건강기능식품(또는 건강기능 음료 첨가물)으로 사용할 경우, 상기 우유 엑소좀을 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용하고, 통상적인 방법에 따라 적절하게 사용할 수 있다. 상기 우유 엑소좀의 혼합량은 그의 사용 목적(예방, 건강 또는 개선, 치료적 처치)에 따라 적합하게 결정될 수 있다. When using the milk exosomes of the present invention as a health functional food (or a health functional beverage additive), the milk exosomes are added as they are or used with other foods or food ingredients, and can be appropriately used according to a conventional method. The mixing amount of the milk exosomes may be appropriately determined according to the purpose of use (prevention, health or improvement, therapeutic treatment).
구체적으로, 상기 우유 엑소좀은 서열번호 5의 염기서열로 이루어진 miR-2478을 포함하는 것일 수 있다.Specifically, the milk exosome may include miR-2478 consisting of the nucleotide sequence of SEQ ID NO: 5.
본 발명 일 실시예에서는 본 발명의 우유 엑소좀이 세포 독성이 없음을 확인하였으며(도 4), 우유 엑소좀을 처리한 경우 티로시나아제의 활성 및 발현이 억제되고, 멜라닌 생합성을 촉진하는 전사인자인 MITF(microphthalmia-associated transcription factor) 의 발현 역시 억제됨을 확인하였다(도 5 내지 도 7). 특히, 피부에 색소를 침착시켜 피부를 어둡게 하는 멜라닌의 합성이 감소하는 것을 직접적으로 확인하였다(도 8). 또한, 본 발명의 우유 엑소좀 내에 마이크로 RNA인 miR-2478이 포함되어 있음을 확인하였다(도 9). In one embodiment of the present invention, it was confirmed that the milk exosomes of the present invention were not cytotoxic (FIG. 4), and when the milk exosomes were treated, the activity and expression of tyrosinase was inhibited, and a transcription factor that promotes melanin biosynthesis It was confirmed that the expression of phosphorus MITF (microphthalmia-associated transcription factor) was also suppressed (FIGS. 5 to 7 ). In particular, it was directly confirmed that the synthesis of melanin, which darkens the skin by depositing a pigment on the skin, decreases (FIG. 8). In addition, it was confirmed that miR-2478, a micro RNA, was contained in the milk exosomes of the present invention (FIG. 9).
상기와 같은 결과로부터 본 발명의 우유 엑소좀을 포함하는 약학적 조성물이 멜라닌 합성을 억제함으로써 과다 색소 침착을 억제할 수 있으며, 멜라닌 합성 및 티로시나아제 활성 등에 기인한 피부 색소 침착 질환에 대해 우수한 치료 효과를 나타낼 수 있음을 확인하였다.From the above results, the pharmaceutical composition containing milk exosomes of the present invention can inhibit hyperpigmentation by inhibiting melanin synthesis, and excellent treatment for skin pigmentation diseases caused by melanin synthesis and tyrosinase activity. It was confirmed that the effect can be exhibited.
본 발명의 약학적 조성물은 투여를 위하여, 상기 본 발명의 우유 엑소좀 외에 약학적으로 허용 가능한 담체, 부형제 또는 희석제를 포함할 수 있다. 상기 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다.The pharmaceutical composition of the present invention may include a pharmaceutically acceptable carrier, excipient, or diluent in addition to the milk exosomes of the present invention for administration. The carrier, excipient and diluent include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline Cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oils.
또한, 본 발명의 약학적 조성물은 어떠한 제형으로도 적용가능하며, 보다 구체적으로 비경구용 제형일 수 있다. 비경구용 제형으로는 주사용, 도포용, 에어로졸 등의 스프레이 형일 수 있다. 더욱 구체적으로는 주사제 형태일 수 있다.In addition, the pharmaceutical composition of the present invention may be applied in any formulation, and more specifically, may be a parenteral formulation. The parenteral formulation may be a spray type such as injection, application, or aerosol. More specifically, it may be in the form of an injection.
비경구 투여를 위한 제제에는 멸균된 수용액, 비수성 용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수성 용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다.Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized formulations, and suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate may be used.
본 발명의 또 다른 측면은 우유 엑소좀을 포함하는 약학적 조성물을 치료를 필요로 하는 개체에 약학적으로 유효한 양으로 투여하는 단계를 포함하는 피부 색소 침착 질환의 치료방법에 관한 것이다. '피부 색소 침착 질환'은 상기 설명한 바와 같다.Another aspect of the present invention relates to a method for treating skin pigmentation disorders comprising administering a pharmaceutical composition containing milk exosomes to a subject in need thereof in a pharmaceutically effective amount. 'Skin pigmentation disease' is as described above.
본 발명에서 "약학적으로 유효한 양"은 의학적 치료에 적용가능한 합리적인 수혜/위험 비율로 질환을 치료하기에 충분한 양을 의미하며, 유효용량 수준은 환자의 성병, 연령, 질병의 종류, 중증도, 약물의 활성, 약물에 대한 민감도, 투여 시간, 투여 경로 및 배출 비율, 치료기간, 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다. In the present invention, "pharmaceutically effective amount" means an amount sufficient to treat a disease at a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level is the patient's sexually transmitted disease, age, type of disease, severity, drug Activity, sensitivity to drugs, time of administration, route of administration and rate of excretion, duration of treatment, factors including concurrent drugs, and other factors well known in the medical field.
본 발명의 약학적 조성물은 개별 치료제로 투여하거나 다른 치료제와 병용하여 투여될 수 있고, 종래의 치료제와 순차적으로 또는 동시에 투여될 수 있다. 또한 본 발명의 약학적 조성물은 단일 또는 다중 투여될 수 있다. 상기 요소를 모두 고려하여 부작용 없이 최소한의 양으로 최대 효과를 얻을 수 있는 양을 투여하는 것이 중요하며, 당업자에 의해 용이하게 결정될 수 있다. The pharmaceutical composition of the present invention may be administered as an individual therapeutic agent or administered in combination with other therapeutic agents, and may be administered sequentially or simultaneously with a conventional therapeutic agent. In addition, the pharmaceutical composition of the present invention may be administered single or multiple. It is important to administer an amount capable of obtaining the maximum effect in a minimum amount without side effects in consideration of all the above factors, and can be easily determined by a person skilled in the art.
본 발명의 용어 "개체"는 본 발명에 따른 약학적 조성물의 투여에 의해 증상이 호전될 수 있는 피부 색소 침착 질환을 가진 동물 또는 인간을 포함한다. 본 발명에 따른 치료용 조성물을 개체에게 투여함으로써, 피부 색소 침착 질환을 효과적으로 예방 및 치료할 수 있다. The term "subject" of the present invention includes animals or humans with a skin pigmentation disorder whose symptoms can be improved by administration of the pharmaceutical composition according to the present invention. By administering the therapeutic composition according to the present invention to an individual, it is possible to effectively prevent and treat skin pigmentation disorders.
본 발명의 용어 "투여"는 어떠한 적절한 방법으로 인간 또는 동물에게 소정의 물질을 도입하는 것을 의미하며, 본 발명에 따른 치료용 조성물의 투여 경로는 목적 조직에 도달할 수 있는 한 어떠한 일반적인 경로를 통하여 경구 또는 비경구 투여될 수 있다. 또한, 본 발명에 따른 치료용 조성물은 유효성분이 표적 세포로 이동할 수 있는 임의의 장치에 의해 투여될 수 있다. The term "administration" of the present invention means introducing a predetermined substance to humans or animals by any suitable method, and the route of administration of the therapeutic composition according to the present invention is through any general route as long as it can reach the target tissue. It can be administered orally or parenterally. In addition, the therapeutic composition according to the present invention can be administered by any device capable of moving the active ingredient to target cells.
본 발명에 따른 약학적 조성물의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. The preferred dosage of the pharmaceutical composition according to the present invention varies depending on the condition and weight of the patient, the degree of the disease, the drug form, the route and duration of administration, but may be appropriately selected by those skilled in the art.
본 발명의 우유 엑소좀을 포함하는 조성물은 독성이 없어 생체 적합성이 우수하며, 티로시나아제 효소 활성 억제 및 멜라닌 합성 억제 효과가 우수하여 피부 미백 및 피부 색소 침착 질환 치료에 널리 활용될 수 있다.The composition containing the milk exosomes of the present invention is non-toxic and has excellent biocompatibility, and has excellent inhibitory effects on tyrosinase enzyme activity and melanin synthesis, and thus can be widely used in skin whitening and treatment of skin pigmentation diseases.
본 발명의 효과는 상기한 효과로 한정되는 것은 아니며, 본 발명의 상세한 설명 또는 청구범위에 기재된 발명의 구성으로부터 추론 가능한 모든 효과를 포함하는 것으로 이해되어야 한다.The effects of the present invention are not limited to the above effects, and should be understood to include all effects that can be deduced from the configuration of the invention described in the detailed description or claims of the present invention.
도 1은 우유 엑소좀의 크기 및 엑소좀 마커를 확인한 결과를 나타낸 것이다.
도 2는 전자현미경을 이용하여 우유 엑소좀의 형태 및 크기를 확인한 결과를 나타낸 것이다.
도 3은 우유 엑소좀의 B16F10 세포 내로의 흡수를 확인한 결과를 나타낸 것이다.
도 4는 우유 엑소좀의 독성 여부를 세포 생존율을 통해 확인한 결과를 나타낸 것이다.
도 5는 우유 엑소좀의 티로시나아제 효과 활성 억제 효과를 확인한 결과를 나타낸 것이다.
도 6은 우유 엑소좀의 티로시나아제 및 MITF 의 mRNA 발현 억제 효과를 확인한 결과를 나타낸 것이다(도 6A: 티로시나아제의 mRNA 발현 억제, 도 6B: MITF의 mRNA 발현 억제).
도 7은 우유 엑소좀의 티로시나아제 및 MITF 의 단백질 발현 억제 효과를 확인한 결과를 나타낸 것이다.
도 8은 우유 엑소좀의 멜라닌 합성 억제 효과를 확인한 결과를 나타낸 것이다.
도 9는 우유 엑소좀 처리에 따른 miR-2478의 발현 증가를 확인한 결과를 나타낸 것이다.1 shows the results of confirming the size and exosome markers of milk exosomes.
2 shows the results of confirming the shape and size of milk exosomes using an electron microscope.
3 shows the results of confirming the absorption of milk exosomes into B16F10 cells.
Figure 4 shows the results of confirming the toxicity of milk exosomes through cell viability.
Figure 5 shows the results of confirming the effect of inhibiting the activity of the tyrosinase effect of the milk exosomes.
Figure 6 shows the results confirming the mRNA expression inhibitory effect of tyrosinase and MITF of milk exosomes (Figure 6A: inhibition of mRNA expression of tyrosinase, Figure 6B: inhibition of mRNA expression of MITF).
7 shows the results of confirming the protein expression inhibitory effect of tyrosinase and MITF of milk exosomes.
Figure 8 shows the results confirming the melanin synthesis inhibitory effect of the milk exosomes.
9 shows the result of confirming the increase in expression of miR-2478 according to the milk exosome treatment.
이하, 본 발명을 실시예에 의해 상세히 설명한다. 단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명이 하기 실시예에 의해 한정되는 것은 아니다.Hereinafter, the present invention will be described in detail by examples. However, the following examples are only illustrative of the present invention, and the present invention is not limited by the following examples.
실시예 1. 우유 엑소좀(milk exosome) 제조방법Example 1. Milk exosome manufacturing method
원심분리기를 이용하여 소 유래 우유에서 엑소좀을 추출하였다. 보다 구체적으로는, 우유를 튜브에 분주하여, 2000g와 10,000g에서 각각 10분 동안 원심분리하여 상층액을 수거하였다. 수거한 상층액을 0.45 μm, 0.2 μm 필터로 여과한 다음, phosphate buffered saline (PBS)를 혼합하였다. 이후, Exoquick exosome precipitation solution (System Biosciences)을 PBS와 혼합하여 넣어 준 후, 30분 동안 휴지시키고, 1500g에서 30분간 다시 원심분리하였다. 상층액을 제거하고 엑소좀 펠렛을 PBS에 용해시켜 이후 실험에 이용하였다.Exosomes were extracted from cow-derived milk using a centrifuge. More specifically, milk was dispensed into a tube, centrifuged at 2000 g and 10,000 g for 10 minutes, respectively, to collect the supernatant. The collected supernatant was filtered through a 0.45 μm, 0.2 μm filter, and then phosphate buffered saline (PBS) was mixed. Thereafter, Exoquick exosome precipitation solution (System Biosciences) was mixed with PBS and put thereinto, then paused for 30 minutes, and centrifuged again at 1500 g for 30 minutes. The supernatant was removed, and the exosome pellet was dissolved in PBS and used in subsequent experiments.
실험예 1. 우유 엑소좀의 특성 확인Experimental Example 1. Characterization of milk exosomes
1-1. 우유 엑소좀의 크기 측정1-1. Measurement of the size of milk exosomes
우유 엑소좀의 크기를 확인하기 위해 동적 광산란 측정(dynamic light scattering, DLS)을 통해 엑소좀의 크기를 측정하였으며, 80~190nm 크기를 나타냄을 확인하였다(도 1).In order to confirm the size of the milk exosomes, the size of the exosomes was measured through dynamic light scattering (DLS), and it was confirmed that the size of the exosomes was 80-190nm (FIG. 1).
1-2. CD9 단백질 발현 확인1-2. Confirmation of CD9 protein expression
엑소좀 마커인 CD9 발현 여부를 웨스턴블롯을 이용하여 확인하였으며, 도 1에 나타난 바와 같이 엑소좀 마커인 CD9 단백질이 엑소좀에서는 뚜렷이 관찰되었으며, 엑소좀 외에 상층액에서는 CD9 발현이 되지 않음을 확인하였다.Whether or not the exosome marker CD9 was expressed was confirmed using Western blot, and as shown in FIG. 1, the exosome marker CD9 protein was clearly observed in the exosome, and it was confirmed that CD9 expression was not in the supernatant other than the exosome. .
우유 엑소좀에서 10% SDS 폴리아크릴마이드 젤을 이용하여 단백질을 분리하였다. 상기 분리한 단백질은 니트로셀룰로오스막(GE Health care)으로 옮긴 후, 항체의 비특이적 결합을 방지하기 위하여 1시간 동안 5% 탈지분유에 반응하였다. CD9(abcam) 1차 항체를 1:1000의 비율로 희석하여 4 ℃에서 12 ~ 18시간 동안 막에 결합시켰다. 이후, HRP-tagged anti-rabbit 항체와 결합시켜 상온에서 30분 동안 반응시켰다. ECL kit(Santa Cruz Inc)를 사용하여 단백질 밴드를 관찰하였다. Proteins were isolated from milk exosomes using 10% SDS polyacrylamide gel. The isolated protein was transferred to a nitrocellulose membrane (GE Health care), and then reacted with 5% skim milk for 1 hour to prevent non-specific binding of the antibody. The CD9 (abcam) primary antibody was diluted in a ratio of 1:1000 and bound to the membrane at 4° C. for 12 to 18 hours. Then, it was combined with the HRP-tagged anti-rabbit antibody and reacted at room temperature for 30 minutes. Protein bands were observed using an ECL kit (Santa Cruz Inc).
1-3. 엑소좀의 형태 및 크기 확인1-3. Confirmation of the shape and size of exosomes
상기 실시예 1에서 추출한 우유 엑소좀의 형태 및 크기를 전자현미경을 이용하여 관찰하였다. 그 결과, 도 2에 나타난 바와 같이 엑소좀이 200nm 크기 내에서 구형으로 존재하는 것을 확인하였다.The shape and size of the milk exosomes extracted in Example 1 were observed using an electron microscope. As a result, it was confirmed that the exosomes exist in a spherical shape within the 200nm size as shown in FIG. 2.
1-4. 엑소좀의 세포 내 흡수 확인1-4. Confirmation of intracellular absorption of exosomes
우유에서 추출한 엑소좀이 세포 내로 흡수되는지 확인하기 위하여, 엑소좀을 PKH26 염색액으로 5분동안 처리하고, 멜라닌 세포인 B16F10 세포에 염색한 엑소좀을 3시간 반응시킨 후 형광을 관찰하였다. In order to confirm whether the exosomes extracted from milk were absorbed into the cells, the exosomes were treated with PKH26 staining solution for 5 minutes, and the exosomes stained on B16F10 cells, which are melanocytes, were reacted for 3 hours, and fluorescence was observed.
구체적으로, 엑소좀 펠렛을 1ml Diluent C를 첨가하고, 따로 1ml의 Diluent C는 4 μl의 PKH26 (Sigma)으로 혼합시켜 stain solution을 만들었다. 상기 stain solution을 Diluent C를 첨가한 엑소좀과 혼합하여 5분 동안 반응시켰고, 1% bovine serum albumin이 더해지면서 반응을 멈추었다. PKH26으로 표지된 엑소좀은 Exoquick exosome precipitation solution(System Biosciences)을 사용하여 제조사의 프로토콜에 따라 추출하였다. 이후 형광 현미경(CELENA S digital imaging system, Logos Biosystems)을 이용하여 관찰하였다.Specifically, 1 ml of Diluent C was added to the exosome pellet, and 1 ml of Diluent C was mixed with 4 μl of PKH26 (Sigma) to prepare a stain solution. The stain solution was mixed with exosomes to which Diluent C was added and reacted for 5 minutes, and the reaction was stopped when 1% bovine serum albumin was added. Exosomes labeled with PKH26 were extracted according to the manufacturer's protocol using Exoquick exosome precipitation solution (System Biosciences). Then, it was observed using a fluorescence microscope (CELENA S digital imaging system, Logos Biosystems).
그 결과, 도 3에 나타난 바와 같이 B16F10 세포 내에 염색된 엑소좀이 들어간 것을 확인하였으며, 이를 통해 우유에서 엑소좀이 추출되었으며, 추출된 엑소좀의 세포 내 흡수가 나타남을 확인하였다. As a result, it was confirmed that the stained exosomes entered into the B16F10 cells as shown in FIG. 3, and through this, the exosomes were extracted from milk, and it was confirmed that intracellular absorption of the extracted exosomes appeared.
실험예 2. 우유 엑소좀의 세포 독성 확인Experimental Example 2. Confirmation of cytotoxicity of milk exosomes
멜라닌 세포인 B16F10 세포를 이용하여 본 발명의 우유 엑소좀에 독성이 있는지 확인하기 위하여, B16F10 세포에 우유 엑소좀을 각각 20 μg/ml 및50 μg/ml을 24시간 동안 처리하여 세포 생존율을 측정하였다. 우유 엑소좀을 처리하지 않은 군을 대조군으로 하였다(Mock).To determine whether the milk exosomes of the present invention are toxic using melanocytes B16F10 cells, the B16F10 cells were treated with
B16F10 세포를 96 웰 플레이트에 5x104 cells/ml이 되도록 분주하고 37℃, 5%, CO2 조건의 배양기에서 24시간 배양하였다. 상기 배양된 세포에 우유 엑소좀을 처리하고, 24시간 동안 배양한 후, EZ-Cyrox 세포생존율 분석키트(Daeil Lab Service)를 사용하여 제조사의 방법에 따라 세포 생존율에 대한 효과를 측정하였다.B16F10 cells were dispensed to a 96 well plate at 5×10 4 cells/ml, and cultured for 24 hours in an incubator at 37°C, 5%, and CO 2 . The cultured cells were treated with milk exosomes and cultured for 24 hours, and then the effect on cell viability was measured according to the manufacturer's method using an EZ-Cyrox cell viability assay kit (Daeil Lab Service).
그 결과, 도 4에 나타난 바와 같이, 대조군과 우유 엑소좀을 처리한 군 모두에서 생존율 변화가 나타나지 않은 바, 본 발명의 우유 엑소좀이 독성이 없음을 확인하였다.As a result, as shown in FIG. 4, there was no change in survival rate in both the control group and the group treated with the milk exosomes, and it was confirmed that the milk exosomes of the present invention were not toxic.
실험예 3. 티로시나아제(Tyrosinase, TYR) 효소 활성 억제Experimental Example 3. Tyrosinase (TYR) enzyme activity inhibition
피부에서는 티로시나아제 효소에 의해 색소침착이 일어나며, 본 발명의 우유 엑소좀에 의해 티로시나아제의 활성이 억제되는지를 확인하였다. B16F10 세포에 우유 엑소좀을 각각 20 μg/ml 및50 μg/ml을 각각 처리하여 티로시나아제의 활성을 측정하였으며, 우유 엑소좀을 처리하지 않은 군을 대조군으로 하였다(Mock).In the skin, it was confirmed whether pigmentation occurs by the tyrosinase enzyme, and the activity of tyrosinase is inhibited by the milk exosomes of the present invention. B16F10 cells were treated with 20 μg/ml and 50 μg/ml of milk exosomes, respectively, to measure the activity of tyrosinase, and the group not treated with milk exosomes was used as a control (Mock).
구체적으로, B16F10세포에 우유 엑소좀을 농도별로 처리하여 24시간 배양한 후 배지를 제거하고 PBS로 세척하였다. 1% Triton X-100, 5mM EDTA, 0.1% 0.1M PMSF(phenylmethyl sulfonyl fluoride)를 혼합한 0.1M 포스페이트 완충용액으로 상기 세포를 수거한 후 얼음에서 30분간 용해시켰다. 그 후, 4℃, 16,500g 조건으로 30분간 원심분리하여 상층액을 티로시나아제 활성 측정 용액으로 사용하였다. 상기 상층액 40 μl에 80 μl의 0.1M 포스페이트 완충용액과 40 μl 티로시나아제를 첨가하였다. 기질로서 40 μl의 10mM DOPA를 첨가한 후 37℃에서 30분간 반응시킨 다음, 플레이트 리더기를 이용하여 파장 475nm에서 흡광도를 측정하였다. Specifically, B16F10 cells were treated with milk exosomes by concentration, cultured for 24 hours, and then the medium was removed and washed with PBS. 1% Triton X-100, 5mM EDTA, 0.1% 0.1M PMSF (phenylmethyl sulfonyl fluoride) mixed with 0.1M phosphate buffer solution, the cells were collected and dissolved in ice for 30 minutes. Thereafter, centrifugation was performed at 4° C. and 16,500 g for 30 minutes, and the supernatant was used as a tyrosinase activity measurement solution. To 40 μl of the supernatant, 80 μl of 0.1M phosphate buffer and 40 μl tyrosinase were added. After adding 40 μl of 10 mM DOPA as a substrate, the reaction was performed at 37° C. for 30 minutes, and the absorbance was measured at a wavelength of 475 nm using a plate reader.
그 결과, 도 5에 나타난 바와 같이, 우유 엑소좀을 20 μg/ml 및 50 μg/ml 농도로 처리한 경우, 대조군에 비해 티로시나아제의 활성이 현저히 감소됨을 확인하였다.As a result, as shown in FIG. 5, when the milk exosomes were treated at concentrations of 20 μg/ml and 50 μg/ml, it was confirmed that the activity of tyrosinase was significantly reduced compared to the control group.
실험예 4. 티로시나아제 및 MITF의 발현 억제 확인Experimental Example 4. Confirmation of inhibition of expression of tyrosinase and MITF
4-1. 실시간 중합효소 연쇄반응(real-time PCR)4-1. Real-time polymerase chain reaction (real-time PCR)
우유 엑소좀이 멜라닌 생합성 과정에 중요한 효소인 티로시나아제 및 전사인자인 MITF(microphthalmia-associated transcription factor) 발현에 영향을 미치는지 확인하기 위하여 실시간 중합효소 연쇄반응(real-time PCR)을 통해 티로시나아제 및 MITF의 mRNA 발현을 확인하였다.To determine whether milk exosomes affect the expression of tyrosinase, an important enzyme in the melanin biosynthesis process, and microphthalmia-associated transcription factor (MITF), a transcription factor, tyrosinase through real-time PCR. And mRNA expression of MITF was confirmed.
B16F10세포에서 우유 엑소좀을 처리 하고 24시간 후에 세포를 수거하였다. 상기 수거한 세포에Tri 시약(Bioline)을 반응시켜 total RNA를 분리하였다. 역전사 반응을 실시하기 위하여 1 μg RNA에 dNTP, M-MLV reverse-transcriptase (Promega) 등을 첨가한 다음 37℃에서 1시간 반응시켜 cDNA를 합성하였다. TYR과 MITF mRNA 발현을 측정하기 위해 SYBR Green PCR Master mix(Bioline)를 이용하여 실시간 중합효소 연쇄반응을 수행하였다. 특정 유전자를 증폭하기 위한 PCR 조건은 다음과 같이 시행하였다. 95℃에서 10분간 반응시킨 다음, 15초 95℃, 15초 60℃, 72℃ 15초를 한 주기로 하여 40 cycles 동안 증폭하였다. 표적 유전자 mRNA 발현량은 actin 발현량에 대한 상대적인 발현량으로 보정하였다. 사용된 프라이머는 하기 표 1에 나타난 바와 같다. B16F10 cells were treated with milk exosomes and cells were harvested 24 hours later. Total RNA was isolated by reacting the collected cells with a Tri reagent (Bioline). In order to perform the reverse transcription reaction, dNTP, M-MLV reverse-transcriptase (Promega), etc. were added to 1 μg RNA and then reacted at 37° C. for 1 hour to synthesize cDNA. Real-time polymerase chain reaction was performed using SYBR Green PCR Master mix (Bioline) to measure TYR and MITF mRNA expression. PCR conditions for amplifying a specific gene were performed as follows. The reaction was performed at 95° C. for 10 minutes, followed by amplification for 40 cycles in one cycle at 95° C. for 15 seconds, 60° C. for 15 seconds and 15 seconds at 72° C. The target gene mRNA expression level was corrected by the relative expression level to the actin expression level. The primers used are as shown in Table 1 below.
그 결과, 도 6A에 나타난 바와 같이 우유 엑소좀을 처리한 경우, 티로시나아제의 mRNA 발현이 억제됨을 확인하였으며, 처리된 우유 엑소좀의 농도가 증가할수록 티로시나아제의 mRNA 발현 억제 효과가 증가함을 확인하였다. 구체적으로, 티로시나아제 mRNA 발현이 20 μg/ml 처리한 처리군에서는 49%, 50 μg/ml을 처리한 처리군에서는 76% 감소함을 확인하였으며, 티로시나아제의 발현 억제 효과가 우수함을 확인하였다.또한, 도 6B에 나타난 바와 같이, 우유 엑소좀을 처리한 경우, 멜라닌 생합성 과정에 중요한 전사인자인 MITF의 mRNA 발현 역시 억제됨을 확인하였으며, 처리된 우유 엑소좀의 농도가 증가할수록 MITF의 mRNA 발현 억제 효과는 증가함을 확인하였다. 구체적으로 MITF mRNA 발현이 20 μg/ml 처리한 처리군에서는 59%, 50 μg/ml을 처리한 처리군에서는 85% 감소함을 확인하였으며, MITF의 mRNA 발현 억제 효과가 우수함을 확인하였다.As a result, as shown in FIG. 6A, when the milk exosomes were treated, it was confirmed that mRNA expression of tyrosinase was inhibited, and as the concentration of the treated milk exosomes increased, the inhibitory effect of tyrosinase mRNA expression increased. Was confirmed. Specifically, it was confirmed that the expression of tyrosinase mRNA was reduced by 49% in the treatment group treated with 20 μg/ml and 76% in the treatment group treated with 50 μg/ml, and the effect of inhibiting the expression of tyrosinase was excellent. In addition, as shown in FIG. 6B, when milk exosomes were treated, it was confirmed that the mRNA expression of MITF, an important transcription factor in the process of melanin biosynthesis, was also suppressed, and as the concentration of the treated milk exosomes increased, the mRNA of MITF It was confirmed that the expression inhibitory effect was increased. Specifically, it was confirmed that MITF mRNA expression was reduced by 59% in the treatment group treated with 20 μg/ml and 85% in the treatment group treated with 50 μg/ml, and it was confirmed that the inhibitory effect of MITF on mRNA expression was excellent.
4-2. 웨스턴블롯(Western blot)4-2. Western blot
우유 엑소좀이 멜라닌 생합성 과정에 중요한 전사인자인 티로시나아제 및 MITF 발현에 영향을 미치는지 확인하기 위하여 티로시나아제 및 MITF의 단백질 발현 정도를 확인하였다.In order to confirm whether milk exosomes affect the expression of tyrosinase and MITF, which are important transcription factors in the melanin biosynthesis process, the degree of protein expression of tyrosinase and MITF was confirmed.
B16F10세포주를 2×105 cells/well로 6 웰 플레이트에 부착시킨 다음, 우유 엑소좀을 처리하고 24시간 동안 배양하였다. 수거한 세포를 16,500g에서 15분간 원심 분리하여 상등액을 취한 후, 단백질 농도를 BSA 키트(Bio-rad)로 정량하였다. The B16F10 cell line was attached to a 6-well plate at 2×10 5 cells/well, and then treated with milk exosomes and cultured for 24 hours. The collected cells were centrifuged at 16,500 g for 15 minutes to take a supernatant, and the protein concentration was quantified with a BSA kit (Bio-rad).
추출한 단백질은 10% SDS 폴리아크릴마이드 젤을 이용하여 단백질을 분리하였다. 상기 분리한 단백질은 니트로셀룰로오스막(GE Health care)으로 옮긴 후, 항체의 비특이적 결합을 방지하기 위하여 1시간 동안 5% 탈지분유에 반응하였다. TYR (abcam), MITF (abcam), Actin (Sigma)의 1차 항체를 1:1000의 비율로 희석하여 4℃에서 12 - 18시간 니트로셀룰로오스막과 반응시켰다. 이후, PBS로 세척한 다음 HRP-tagged anti-rabbit 항체를 첨가하여 상온에서 30분 동안 반응시켰다. ECL 키트 (Santa Cruz Inc.)를 사용하여 단백질 밴드를 관찰하였다. The extracted protein was separated using a 10% SDS polyacrylamide gel. The isolated protein was transferred to a nitrocellulose membrane (GE Health care), and then reacted with 5% skim milk for 1 hour to prevent non-specific binding of the antibody. Primary antibodies of TYR (abcam), MITF (abcam), and Actin (Sigma) were diluted in a ratio of 1:1000 and reacted with the nitrocellulose membrane at 4° C. for 12 to 18 hours. Thereafter, after washing with PBS, HRP-tagged anti-rabbit antibody was added and reacted at room temperature for 30 minutes. Protein bands were observed using an ECL kit (Santa Cruz Inc.).
그 결과, 도 7에 나타난 바와 같이 우유 엑소좀을 처리한 경우, mRNA의 발현이 감소된 것과 마찬가지로, 티로시나아제 및 MITF의 단백질 발현이 모두 감소된 것을 확인하였으며, 처리된 우유 엑소좀의 농도가 증가할수록 티로시나아제 및 MITF의 단백질 발현 억제 효과는 증가함을 확인하였다. 상기와 같은 결과는 본 발명의 우유 엑소좀이 미백 효과를 유도함을 나타내는 것이다.As a result, as shown in FIG. 7, when the milk exosomes were treated, it was confirmed that the expression of both tyrosinase and MITF proteins was reduced, just as the expression of mRNA was reduced, and the concentration of the treated milk exosomes was It was confirmed that the inhibitory effect of tyrosinase and MITF on protein expression increased as the increase increased. The above results indicate that the milk exosomes of the present invention induce a whitening effect.
실험예 5. 멜라닌 합성 억제효과 확인Experimental Example 5. Confirmation of melanin synthesis inhibitory effect
직접적으로 피부색을 결정하는 멜라닌을 억제시키는 우유 엑소좀의 효능을 알아보고자 B16F10 세포에 우유 엑소좀을 처리하여 멜라닌 함량을 측정하였다.In order to investigate the efficacy of milk exosomes that directly inhibit melanin, which determines skin color, the B16F10 cells were treated with milk exosomes to measure the melanin content.
B16F10 세포주에 우유 엑소좀을 각각 20 μg/ml, 50 μg/ml 농도로 처리한 다음, 24시간 동안 배양하고 세포를 수거하였다. 회수한 세포에 10% DMSO를 포함하는 1N NaOH를 첨가한 다음 90℃에서 1시간 반응시켜 멜라닌이 충분히 용출될 수 있도록 한 후 플레이트 리더기를 이용하여 파장 405nm에서 흡광도를 측정하였다. The B16F10 cell line was treated with milk exosomes at concentrations of 20 μg/ml and 50 μg/ml, respectively, and then cultured for 24 hours and the cells were harvested. 1N NaOH containing 10% DMSO was added to the recovered cells and then reacted at 90° C. for 1 hour so that melanin could be sufficiently eluted, and then absorbance was measured at a wavelength of 405 nm using a plate reader.
그 결과, 도 8에 나타난 바와 같이 우유 엑소좀을 처리한 경우, 멜라닌 합성이 저해되는 것을 확인하였으며, 처리된 우유 엑소좀의 농도가 증가할수록 멜라닌 합성 억제 효과가 증가함을 확인하였다. 구체적으로, 우유 엑소좀20 μg/ml 처리한 처리군에서는 43%, 50 μg/ml을 처리한 처리군에서는 58% 감소함을 확인하였으며, 이로부터 직접적으로 멜라닌 합성을 억제하는 효과가 우수함을 확인하였다.As a result, as shown in FIG. 8, when the milk exosomes were treated, it was confirmed that melanin synthesis was inhibited, and as the concentration of the treated milk exosomes increased, it was confirmed that the melanin synthesis inhibitory effect increased. Specifically, it was confirmed that it was reduced by 43% in the treatment group treated with
실험예 6. 우유 엑소좀 내의 miRNA(microRNA) 확인Experimental Example 6. Confirmation of miRNA (microRNA) in milk exosomes
피부 색소 침착에 관여하는 우유 엑소좀 내의 microRNA을 확인하였다. 소에 서 유래한 우유 엑소좀을 이용하여 microRNA 프로파일링을 조사한 결과, miR-2478이 가장 많이 존재한다는 연구 결과가 보고된 바 있음에 따라(Izumi, H., Tsuda, M., Sato, Y., Kosaka, N., Ochiya, T., Iwamoto, H., Namba, K., andTakeda, Y. (2015). Bovine milk exosomes contain microRNA and mRNA and are taken up by human macrophages. J. Dairy Sci. 98, 2920-2933.), 본 발명에서는 우유 엑소좀을 처리함에 따라 miR-2478이 증가하는지 확인하였다.MicroRNAs in milk exosomes involved in skin pigmentation were identified. As a result of microRNA profiling using cow-derived milk exosomes, research results showing that miR-2478 is the most present have been reported (Izumi, H., Tsuda, M., Sato, Y. , Kosaka, N., Ochiya, T., Iwamoto, H., Namba, K., andTakeda, Y. (2015).Bovine milk exosomes contain microRNA and mRNA and are taken up by human macrophages. J. Dairy Sci. 98 , 2920-2933.), in the present invention, it was confirmed whether miR-2478 was increased as milk exosomes were treated.
B16F10 세포에 우유 엑소좀을 20 μg/ml, 50 μg/ml 농도로 처리한 후 miR-2478의 발현을 확인하였다. 상기 miR-2478의 서열은 아래와 같다.B16F10 cells were treated with milk exosomes at concentrations of 20 μg/ml and 50 μg/ml, and then the expression of miR-2478 was confirmed. The sequence of the miR-2478 is as follows.
6웰 플레이트 상에 B16F10 세포를 2x105 cells/well 의 농도로 분주하고, 우유 엑소좀을 농도 별로 24시간 동안 처리하였다. 그 후, 세포를 수거하고, 1ml의 TRI 시약(Bioline)을 이용하여 추출한 총 RNA 100ng에 miScript Reverse Transcription kit(Qiagen)을 활용하여 cDNA를 합성하였다. 합성된 생산물 2 μl를 miScript SYBR Green kit(Qiagen)를 사용하여 PCR 반응을 실시하였다. 다음과 같은 PCR 조건 하에서 유전자를 증폭시켰다. 즉, Roto gene Q PCR 기기(Qiagen)을 이용하여 94°C 에서15 분, 그 후 94°C에서 15초, 55°C에서 30초 및 70°C에서 20 초의 40주기로 증폭시켰다. 유전자 발현은 SNORD61 발현으로 보정하였으며, miR-2478 검출용 miRNA 특이적 프라이머는 QIAGEN(miScript primer assay)으로 부터 구매하였다.B16F10 cells were dispensed on a 6-well plate at a concentration of 2×10 5 cells/well, and milk exosomes were treated for 24 hours at each concentration. Thereafter, the cells were harvested, and cDNA was synthesized using a miScript Reverse Transcription kit (Qiagen) in 100 ng of total RNA extracted using 1 ml of TRI reagent (Bioline). 2 μl of the synthesized product was subjected to PCR reaction using miScript SYBR Green kit (Qiagen). The gene was amplified under the following PCR conditions. That is, it was amplified in 40 cycles of 15 minutes at 94°C, 15 seconds at 94°C, 30 seconds at 55°C, and 20 seconds at 70°C using a Roto gene Q PCR instrument (Qiagen). Gene expression was corrected by SNORD61 expression, and miRNA-specific primers for miR-2478 detection were purchased from QIAGEN (miScript primer assay).
그 결과, 도 9에 나타난 바와 같이 우유 엑소좀을 처리한 경우, miR-2478의 발현이 증가되는 것을 확인하였으며, 처리된 우유 엑소좀의 농도가 증가할수록 miR-2478의 발현이 증가함을 확인하였다. 이를 통해 우유 엑소좀이 세포에 들어가면 세포내의 miR-2478이 우유 엑소좀 농도 의존적으로 증가하는 것을 알 수 있었다.As a result, as shown in FIG. 9, when the milk exosomes were treated, it was confirmed that the expression of miR-2478 was increased, and as the concentration of the treated milk exosomes increased, the expression of miR-2478 was confirmed to increase. . Through this, it was found that when the milk exosomes enter the cell, the intracellular miR-2478 increases in a milk exosome concentration-dependent manner.
상기와 같은 결과로부터 본 발명의 우유 엑소좀은 세포 독성이 없으면서도 티로시나아제 효소 활성 및 멜라닌 합성을 억제함으로써 미백 효과를 나타냄을 확인하였다. 이에 따라, 본 발명의 우유 엑소좀은 피부 미백용으로 널리 활용될 수 있다.From the above results, it was confirmed that the milk exosomes of the present invention exhibit a whitening effect by inhibiting tyrosinase enzyme activity and melanin synthesis even without cytotoxicity. Accordingly, the milk exosomes of the present invention can be widely used for skin whitening.
전술한 본 발명의 설명은 예시를 위한 것이며, 본 발명이 속하는 기술분야의 통상의 지식을 가진 자는 본 발명의 기술적 사상이나 필수적인 특징을 변경하지 않고서 다른 구체적인 형태로 쉽게 변형이 가능하다는 것을 이해할 수 있을 것이다. 그러므로 이상에서 기술한 실시예들은 모든 면에서 예시적인 것이며 한정적이 아닌 것으로 이해해야만 한다. 예를 들어, 단일형으로 설명되어 있는 각 구성 요소는 분산되어 실시될 수도 있으며, 마찬가지로 분산된 것으로 설명되어 있는 구성 요소들도 결합된 형태로 실시될 수 있다. The above description of the present invention is for illustrative purposes only, and those of ordinary skill in the art to which the present invention pertains will be able to understand that it can be easily modified into other specific forms without changing the technical spirit or essential features of the present invention. will be. Therefore, it should be understood that the embodiments described above are illustrative in all respects and not limiting. For example, each component described as a single type may be implemented in a distributed manner, and similarly, components described as being distributed may also be implemented in a combined form.
본 발명의 범위는 후술하는 청구범위에 의하여 나타내어지며, 청구범위의 의미 및 범위 그리고 그 균등 개념으로부터 도출되는 모든 변경 또는 변형된 형태가 본 발명의 범위에 포함되는 것으로 해석되어야 한다.The scope of the present invention is indicated by the claims to be described later, and all changes or modified forms derived from the meaning and scope of the claims and the concept of equivalents thereof should be construed as being included in the scope of the present invention.
<110> University-Industry Cooperation Group of Kyung Hee University
<120> SKIN WHITENING COMPOSITION COMPRISING MILK EXOSOMES
<130> 19PP30076
<160> 5
<170> KoPatentIn 3.0
<210> 1
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> TYR Forward primer
<400> 1
cgagcctgtg cctcctctaa 20
<210> 2
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> TYR Reverse primer
<400> 2
ccaggactca cggtcatcca 20
<210> 3
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<223> MITF Forward primer
<400> 3
caaatggcaa atacgttacc cg 22
<210> 4
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<223> MITF Reverse primer
<400> 4
caatgctctt gcttcagact ct 22
<210> 5
<211> 20
<212> RNA
<213> Artificial Sequence
<220>
<223> miR-2478
<400> 5
guaucccacu ucugacacca 20
<110> University-Industry Cooperation Group of Kyung Hee University
<120> SKIN WHITENING COMPOSITION COMPRISING MILK EXOSOMES
<130> 19PP30076
<160> 5
<170> KoPatentIn 3.0
<210> 1
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> TYR Forward primer
<400> 1
cgagcctgtg cctcctctaa 20
<210> 2
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> TYR Reverse primer
<400> 2
ccaggactca cggtcatcca 20
<210> 3
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<223> MITF Forward primer
<400> 3
caaatggcaa atacgttacc cg 22
<210> 4
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<223> MITF Reverse primer
<400> 4
caatgctctt gcttcagact ct 22
<210> 5
<211> 20
<212> RNA
<213> Artificial Sequence
<220>
<223> miR-2478
<400> 5
Claims (8)
상기 우유 엑소좀은 서열번호 5의 염기서열로 이루어진 miR-2478을 포함하는 것인, 피부 미백용 조성물.The method of claim 1,
The milk exosomes comprising miR-2478 consisting of the nucleotide sequence of SEQ ID NO: 5, skin whitening composition.
상기 우유 엑소좀은 소 유래인 것인, 피부 미백용 조성물.The method of claim 1,
The milk exosome is derived from cows, skin whitening composition.
상기 피부 미백용 조성물은 화장료 조성물인 것인, 피부 미백용 조성물.The method of claim 1,
The skin whitening composition is a cosmetic composition, skin whitening composition.
상기 피부 미백용 조성물은 식품 조성물인 것인, 피부 미백용 조성물.The method of claim 1,
The skin whitening composition is a food composition, skin whitening composition.
상기 우유 엑소좀은 서열번호 5의 염기서열로 이루어진 miR-2478을 포함하는 것인, 피부 색소 침착 질환의 예방 또는 치료용 약학적 조성물.The method of claim 6,
The milk exosomes comprising miR-2478 consisting of the nucleotide sequence of SEQ ID NO: 5, a pharmaceutical composition for preventing or treating skin pigmentation diseases.
상기 우유 엑소좀은 소 유래인 것인, 피부 색소 침착 질환의 예방 또는 치료용 약학적 조성물.The method of claim 6,
The milk exosomes are derived from cows, a pharmaceutical composition for preventing or treating skin pigmentation diseases.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020190048320A KR102186872B1 (en) | 2019-04-25 | 2019-04-25 | Skin whitening composition comprising milk exosomes |
| PCT/KR2020/005375 WO2020218846A1 (en) | 2019-04-25 | 2020-04-23 | Skin-whitening composition including milk exosome |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020190048320A KR102186872B1 (en) | 2019-04-25 | 2019-04-25 | Skin whitening composition comprising milk exosomes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20200124896A KR20200124896A (en) | 2020-11-04 |
| KR102186872B1 true KR102186872B1 (en) | 2020-12-04 |
Family
ID=72940772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020190048320A KR102186872B1 (en) | 2019-04-25 | 2019-04-25 | Skin whitening composition comprising milk exosomes |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR102186872B1 (en) |
| WO (1) | WO2020218846A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230015622A (en) | 2021-07-23 | 2023-01-31 | 주식회사 팜스킨 | Colostrum hydrolysis product and skin whitening composition containing it |
| KR20230080556A (en) | 2021-11-30 | 2023-06-07 | 주식회사 팜스킨 | Colostrum hydrolysis product and skin improvement composition containing it |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4066816A4 (en) * | 2019-11-28 | 2024-03-06 | Exogenique Co Ltd | Novel use of milk exosomes |
| KR20220041543A (en) | 2020-09-25 | 2022-04-01 | 주식회사 엘지에너지솔루션 | Pouch-type battery case forming apparatus comprising volatile lubricant supply unit and method of manufacturing pouch-type battery case using the same |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013172793A1 (en) * | 2012-05-18 | 2013-11-21 | Agency For Science, Technology & Research | Umbilical cord mesenchymal stem cell exosomes |
| KR101663912B1 (en) * | 2015-01-08 | 2016-10-10 | 한양대학교 에리카산학협력단 | Cosmetic composition containing exosomes extracted from stem cell for skin whitening, antiwrinkle or regeneration |
| KR20160110829A (en) * | 2015-03-13 | 2016-09-22 | 주식회사한국야쿠르트 | The milk fermented product using Lactobacillus paracasei HY7301 for skin whitening and products containing thereof as effective component |
| KR102598793B1 (en) * | 2015-09-23 | 2023-11-07 | (주)아모레퍼시픽 | Composition comprising ginseng derived exosome like vesicles for skin whitening |
| KR101885501B1 (en) * | 2017-11-16 | 2018-08-06 | (주)프로스테믹스 | Functional composition comprising deer antlers derived stem cell culture medium |
-
2019
- 2019-04-25 KR KR1020190048320A patent/KR102186872B1/en active IP Right Grant
-
2020
- 2020-04-23 WO PCT/KR2020/005375 patent/WO2020218846A1/en active Application Filing
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230015622A (en) | 2021-07-23 | 2023-01-31 | 주식회사 팜스킨 | Colostrum hydrolysis product and skin whitening composition containing it |
| KR20230080556A (en) | 2021-11-30 | 2023-06-07 | 주식회사 팜스킨 | Colostrum hydrolysis product and skin improvement composition containing it |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200124896A (en) | 2020-11-04 |
| WO2020218846A1 (en) | 2020-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102186872B1 (en) | Skin whitening composition comprising milk exosomes | |
| TW200902077A (en) | Whitening agent comprising equol or its saccharide derivative as an effective ingredient | |
| CN110278706B (en) | Composition for improving skin beauty comprising extract of fermented soybean fermented with strain of Aspergillus coronarius | |
| TWI747280B (en) | Fermentation product of phyllanthus emblica extract and preparation and use of the same | |
| US10251862B2 (en) | Cosmetic composition containing hydroxy pyranone derivative compound for promoting differentiation of adipocytes | |
| KR101902317B1 (en) | Enzyme treated Mugunghwa extracts for improving skin wrinkle | |
| KR101489935B1 (en) | Method for preparing mugwort extract and cosmetic composition comprising mugwort extract prepared therefrom | |
| KR20140056990A (en) | Composition for preventing or treating alopecia, or promoting hair growth comprising baicalin | |
| KR102122614B1 (en) | Composition comprising Tetrathelmis tetrathele extract for improving condition of hair and preventing hair loss | |
| CN106999528A (en) | For preventing hair loss or stimulating the composition for including high mountain radix scutellariae extract of natural on-off cycles of hair growth | |
| KR20160068315A (en) | Skin whitening composition comprising an extract obtained from carthamus tinctorius l. | |
| KR102239415B1 (en) | Composition for improving skin beauty comprising extract of fermented roots of Panax notoginseng by Aspergillus cristatus strain | |
| KR102287153B1 (en) | Composition for enhancing skin elasticity and improving wrinkles comprising milk exosomes | |
| KR102292961B1 (en) | MELANIN PRODUCTION INHIBITING COMPOSITION COMPRISING microRNA-2478 | |
| KR102039608B1 (en) | Composition including midodrine and its uses | |
| JP2004203812A (en) | Oral composition and bleaching agent containing the same as essential component | |
| KR20170119422A (en) | Cosmetic compositions for improving of skin comprising the extract of Piper cambodianum | |
| KR102613802B1 (en) | Composition for skin whitening comprising culture of Lactobacillus reuteri and extract of Cnidium Monnieri | |
| KR101526435B1 (en) | Compositions for skin-whitening comprising extract of Vitis amurensis ruprecht | |
| KR102345626B1 (en) | siRNA oligonucleotides that inhibit Rap1a expression, and composition for inhibiting melanin prod uction comprising the same | |
| KR102591604B1 (en) | Pharmaceutical composition for preventing or treating hair loss comprising Connarus semidecandrus Jack. extract | |
| KR102326086B1 (en) | Composition for Improving Skin Conditions Having Skin Whitening, Moisturizing, Anti-Wrinkle and Skin Barrier Property Comprising Complex Extracts of Broussonetia kazinoki as Active Ingredient | |
| KR101376197B1 (en) | Composition comprising extract of Hirudo nipponica Whitman for inhibiting synthesis of melanin | |
| KR102225547B1 (en) | Cosmetic composition comprising substance P for whitening skin | |
| KR102600558B1 (en) | Composition for promoting hair growth and preventing hair loss comprising atraric acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |